FMJ-045

FMJ-045 (also known as FMJ-01-045) is a novel, selective dopamine D4 receptor (D4R) low-efficacy partial agonist developed by researchers at Rowan University and High Point University. It was designed using click chemistry to bioisosterically replace the metabolically unstable amide linker of previous D4R ligands with a 1,2,3-triazole linker, thereby improving its in vivo pharmacokinetic stability. FMJ-045 acts functionally as an antagonist at the D4R. Preclinical studies in rodent models have shown that FMJ-045 can attenuate amphetamine-induced risky choice behavior and restore lose-shift behavior in probabilistic discounting tasks without altering baseline decision-making or locomotor activity [1.1]. This suggests therapeutic potential for FMJ-045 in treating neuropsychiatric disorders characterized by executive dysfunction, aberrant catecholamine activity in the prefrontal cortex, and maladaptive risk-taking behavior, such as attention-deficit/hyperactivity disorder (ADHD) and substance use disorders.